Literature DB >> 31482274

[Extramammary Paget's disease].

I Cosgarea1, A Zaremba2, U Hillen3.   

Abstract

Extramammary Paget's disease (EPD) is a rare, slowly growing, cutaneous adenocarcinoma with an incidence of 0.1-2.4 per 1,000,000 inhabitants. Histologically, EPD is characterized by the presence of epidermal Paget's cells, similarly to mammary Paget's disease. The EPD is typically divided into primary EPD (type I) and secondary EPD (type II associated with colorectal carcinoma and type III associated with urogenital carcinoma). From a clinical point of view, EPD is unspecific commonly mimicking chronic inflammatory skin disorders. This unspecific clinical picture can impede and delay the diagnosis of EPD. The treatment of choice for local EPD is the micrographically controlled excision. The extent of the infiltration of adnexal structures should be histologically determined prior to topical therapies, such as imiquimod and superficial ablative therapy. The complete excision of the tumor can be challenging due to ill-defined borders. In the metastatic stage the EPD has a poor prognosis. Controlled clinical trials for systemic treatment are still lacking.

Entities:  

Keywords:  Adnexal infiltration; Cutaneous adenocarcinoma; Excision; Microscopically controlled surgery; Paget’s carcinoma

Mesh:

Year:  2019        PMID: 31482274     DOI: 10.1007/s00105-019-4459-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  54 in total

Review 1.  Mammary and extramammary Paget's disease.

Authors:  J Lloyd; A M Flanagan
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

Review 2.  Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports.

Authors:  Jennifer C Zampogna; Franklin P Flowers; William I Roth; Ashraf M Hassenein
Journal:  J Am Acad Dermatol       Date:  2002-10       Impact factor: 11.527

3.  Carcinoma of Moll's glands with extramammary Paget's disease of the eyelid.

Authors:  C M WHORTON; J B PATTERSON
Journal:  Cancer       Date:  1955 Sep-Oct       Impact factor: 6.860

4.  Androgen-deprivation regimen for multiple bone metastases of extramammary Paget disease.

Authors:  K Yoneyama; N Kamada; K Kinoshita; T Kawashima; M Otani; H Endo; H Shinkai; A Utani
Journal:  Br J Dermatol       Date:  2005-10       Impact factor: 9.302

5.  Extramammary Paget's disease of the external ear canal in association with ceruminous gland carcinoma. A case report.

Authors:  Z Fligiel; M Kaneko
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

Review 6.  Mammary and extramammary Paget's disease.

Authors:  J Kanitakis
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-05       Impact factor: 6.166

7.  Epidemiology and treatment of extramammary Paget disease in the Netherlands.

Authors:  S Siesling; M A G Elferink; J A A M van Dijck; J P E N Pierie; W A M Blokx
Journal:  Eur J Surg Oncol       Date:  2007-01-09       Impact factor: 4.424

8.  Androgen receptors are frequently expressed in mammary and extramammary Paget's disease.

Authors:  Bernadette Liegl; Lars-Christian Horn; Farid Moinfar
Journal:  Mod Pathol       Date:  2005-10       Impact factor: 7.842

9.  Extramammary Paget's disease: surgical treatment with Mohs micrographic surgery.

Authors:  Ali Hendi; David G Brodland; John A Zitelli
Journal:  J Am Acad Dermatol       Date:  2004-11       Impact factor: 11.527

10.  Extramammary Paget disease is characterized by the consistent lack of estrogen and progesterone receptors but frequently expresses androgen receptor.

Authors:  E Diaz de Leon; M L Carcangiu; V G Prieto; P A McCue; J L Burchette; G To; B A Norris; A J Kovatich; R L Sanchez; H R Krigman; Z Gatalica
Journal:  Am J Clin Pathol       Date:  2000-04       Impact factor: 2.493

View more
  1 in total

1.  The Msi1-mTOR pathway drives the pathogenesis of mammary and extramammary Paget's disease.

Authors:  Yongli Song; Christian F Guerrero-Juarez; Zhongjian Chen; Yichen Tang; Xianghui Ma; Cong Lv; Xueyun Bi; Min Deng; Lina Bu; Yuhua Tian; Ruiqi Liu; Ran Zhao; Jiuzhi Xu; Xiaole Sheng; Sujuan Du; Yeqiang Liu; Yunlu Zhu; Shi-Jun Shan; Hong-Duo Chen; Yiqiang Zhao; Guangbiao Zhou; Jianwei Shuai; Fazheng Ren; Lixiang Xue; Zhaoxia Ying; Xing Dai; Christopher J Lengner; Bogi Andersen; Maksim V Plikus; Qing Nie; Zhengquan Yu
Journal:  Cell Res       Date:  2020-05-26       Impact factor: 46.297

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.